Journal
Journal of Clinical Oncology
Publication Date
9-19-2024
Volume
43
Issue
2
First Page
201
Last Page
213
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02018
Rights and Permissions
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10;43(2):201-213. doi: 10.1200/JCO.23.02018. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Gyurkocza, Boglarka; Abboud, Camille; and et al., "Randomized phase III SIERRA trial of 131I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed/refractory AML." Journal of Clinical Oncology. 43, 2. 201 - 213. (2024).
https://digitalcommons.wustl.edu/oa_4/4673
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
